Bioenvision's Evoltra(R) Advertisement Wins Industry Honor

  
    
  
  
    
      Bioenvision, Inc. (NasdaqGM: BIVN) announced today the advertisement for 
      its pediatric leukemia drug Evoltra® 
      has been given the RX Club Show’s “Award 
      of Excellence” for 2006.
    
    
      Founded in 1986 to showcase the top healthcare advertising from around 
      the world, the RX Club Show is an annual international competition that 
      honors the best examples of medical advertising and marketing.
    
    
      “We are proud to be honored with such a 
      prestigious award," said Rob Bradbury, European Marketing Manager, 
      Bioenvision. “It is peer recognition of our 
      marketing excellence, and the innovation that Bioenvision has 
      demonstrated in getting the Evoltra® 
      brand and messages to our target audience.”
    
    
      Hugh Griffith, Chief Operating Officer added; “This 
      further demonstrates the quality of our European sales and marketing 
      organization and our ability to excel within the industry.”
    
    
      The winning Evoltra® advertisement 
      features a young boy on a beach being held in the air in his father’s 
      arms. The caption says “Time 2 keep dreams 
      alive” which symbolizes the potential for 
      Evoltra® to send a 
      child’s leukemia into remission, giving him 
      or her the opportunity to get a transplant and lead a full life.
    
    
      Evoltra® was 
      approved by the European Commission in May 2006 and is available in all 
      25 countries of the European Union.
    
    
      About Evoltra® 
      (clofarabine)
    
    
      The European Marketing Authorization for Evoltra® 
      (clofarabine) is for "the treatment of acute lymphoblastic leukemia 
      (ALL) in pediatric patients who have relapsed or are refractory to at 
      least two prior regimens and where there is no other treatment option 
      anticipated to result in a durable response. Safety and efficacy have 
      been assessed in studies of patients less than or equal to 21 years old 
      at initial diagnosis."
    
    
      Clofarabine is in clinical development for the treatment of other 
      hematological cancers and solid tumors. Bioenvision is also conducting 
      Phase I studies of Evoltra® 
      for the treatment of psoriasis and is planning further worldwide 
      development of Evoltra® 
      in autoimmune diseases.
    
    
      Evoltra® (clofarabine) 
      is a next generation purine nucleoside analog. Bioenvision holds an 
      exclusive worldwide license (excluding U.S. and Canada) for the cancer 
      applications of clofarabine and an exclusive worldwide license for all 
      non-cancer indications. Bioenvision granted an exclusive sublicense to 
      Genzyme Corporation to develop and commercialize clofarabine for certain 
      cancer indications in the U.S. and Canada, which Genzyme markets under 
      the name of Clolar®. 
      Bioenvision originally obtained clofarabine development and 
      commercialization rights under patents held by Southern Research 
      Institute.
    
    
      Clofarabine has been granted orphan drug designation for the treatment 
      of both ALL and AML in the U.S. and Europe. In Europe, the designation 
      provides marketing exclusivity for 10 years following Marketing 
      Authorization.
    
    
      About Bioenvision
    
    
      Bioenvision's primary focus is the acquisition, development, 
      distribution and marketing of compounds and technologies for the 
      treatment of cancer. Bioenvision has a broad pipeline of products for 
      the treatment of cancer, including: Evoltra®, 
      Modrenal® (for which 
      Bioenvision has obtained regulatory approval for marketing in the United 
      Kingdom for the treatment of post-menopausal breast cancer following 
      relapse to initial hormone therapy), and other products. Bioenvision is 
      also developing anti-infective technologies, including the OLIGON® 
      technology; an advanced biomaterial that has been incorporated into 
      various FDA approved medical devices and Suvus®, 
      an antimicrobial agent currently in clinical development for refractory 
      chronic hepatitis C infection. For more information on Bioenvision 
      please visit our Web site at www.bioenvision.com.
    
    
      Certain statements contained herein are "forward-looking" statements 
      (as such term is defined in the Private Securities Litigation Reform Act 
      of 1995). Because these statements include risks and uncertainties, 
      actual results may differ materially from those expressed or implied by 
      such forward-looking statements. Specifically, factors that could cause 
      actual results to differ materially from those expressed or implied by 
      such forward-looking statements include, but are not limited to: risks 
      associated with preclinical and clinical developments in the 
      biopharmaceutical industry in general and in Bioenvision's compounds 
      under development in particular; the potential failure of Bioenvision's 
      compounds under development to prove safe and effective for treatment of 
      disease; uncertainties inherent in the early stage of Bioenvision's 
      compounds under development; failure to successfully implement or 
      complete clinical trials; failure to receive marketing clearance from 
      regulatory agencies for our compounds under development; acquisitions, 
      divestitures, mergers, licenses or strategic initiatives that change 
      Bioenvision's business, structure or projections; the development of 
      competing products; uncertainties related to Bioenvision's dependence on 
      third parties and partners; and those risks described in Bioenvision's 
      filings with the SEC. Bioenvision disclaims any obligation to update 
      these forward-looking statements.
    
  
Bioenvision, Inc. (NasdaqGM: BIVN) announced today the
advertisement for its pediatric leukemia drug Evoltra(R) has been
given the RX Club Show's "Award of Excellence" for 2006.

   Founded in 1986 to showcase the top healthcare advertising from
around the world, the RX Club Show is an annual international
competition that honors the best examples of medical advertising and
marketing.

   "We are proud to be honored with such a prestigious award," said
Rob Bradbury, European Marketing Manager, Bioenvision. "It is peer
recognition of our marketing excellence, and the innovation that
Bioenvision has demonstrated in getting the Evoltra(R) brand and
messages to our target audience."

   Hugh Griffith, Chief Operating Officer added; "This further
demonstrates the quality of our European sales and marketing
organization and our ability to excel within the industry."

   The winning Evoltra(R) advertisement features a young boy on a
beach being held in the air in his father's arms. The caption says
"Time 2 keep dreams alive" which symbolizes the potential for
Evoltra(R) to send a child's leukemia into remission, giving him or
her the opportunity to get a transplant and lead a full life.

   Evoltra(R) was approved by the European Commission in May 2006 and
is available in all 25 countries of the European Union.

   About Evoltra(R) (clofarabine)

   The European Marketing Authorization for Evoltra(R) (clofarabine)
is for "the treatment of acute lymphoblastic leukemia (ALL) in
pediatric patients who have relapsed or are refractory to at least two
prior regimens and where there is no other treatment option
anticipated to result in a durable response. Safety and efficacy have
been assessed in studies of patients less than or equal to 21 years
old at initial diagnosis."

   Clofarabine is in clinical development for the treatment of other
hematological cancers and solid tumors. Bioenvision is also conducting
Phase I studies of Evoltra(R) for the treatment of psoriasis and is
planning further worldwide development of Evoltra(R) in autoimmune
diseases.

   Evoltra(R) (clofarabine) is a next generation purine nucleoside
analog. Bioenvision holds an exclusive worldwide license (excluding
U.S. and Canada) for the cancer applications of clofarabine and an
exclusive worldwide license for all non-cancer indications.
Bioenvision granted an exclusive sublicense to Genzyme Corporation to
develop and commercialize clofarabine for certain cancer indications
in the U.S. and Canada, which Genzyme markets under the name of
Clolar(R). Bioenvision originally obtained clofarabine development and
commercialization rights under patents held by Southern Research
Institute.

   Clofarabine has been granted orphan drug designation for the
treatment of both ALL and AML in the U.S. and Europe. In Europe, the
designation provides marketing exclusivity for 10 years following
Marketing Authorization.

   About Bioenvision

   Bioenvision's primary focus is the acquisition, development,
distribution and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products for
the treatment of cancer, including: Evoltra(R), Modrenal(R) (for which
Bioenvision has obtained regulatory approval for marketing in the
United Kingdom for the treatment of post-menopausal breast cancer
following relapse to initial hormone therapy), and other products.
Bioenvision is also developing anti-infective technologies, including
the OLIGON(R) technology; an advanced biomaterial that has been
incorporated into various FDA approved medical devices and Suvus(R),
an antimicrobial agent currently in clinical development for
refractory chronic hepatitis C infection. For more information on
Bioenvision please visit our Web site at www.bioenvision.com.

   Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.